Case Details
- Citation: [2025] SGHC 12
- Title: Banner (China) Investment Co Ltd v Ang Tjun Min Jimmy
- Court: High Court of the Republic of Singapore (General Division)
- Date of Decision: 20 January 2025
- Judges: Kwek Mean Luck J
- Originating Claim No: 192 of 2022
- Summons No: 1022 of 2024
- Procedural Context: Single Application Pending Trial (SAPT)
- Type of Application: Application for appointment of a common expert and consequential directions on obtaining signature specimens for handwriting analysis
- Plaintiff/Applicant: Banner (China) Investment Co Ltd (“Banner”)
- Defendant/Respondent: Ang Tjun Min Jimmy (“Mr Ang” / “Ang Jimmy Tjun Min”)
- Legal Area: Civil Procedure — selection of specimen signatures for submission to handwriting expert
- Statutes Referenced: Evidence Act 1893 (2020 Rev Ed) (“EA”), including ss 73 and 75
- Evidence Act Version Noted: Evidence Act 1893 (2020 Rev Ed)
- Cases Cited: Tung Kean Hin & Another (as executor for the estate of Tung Leong Geok, deceased) v Yuen Heng Phong (as administrator for the estate of See Ngan Sang @ Lee Ngan Sang) [2019] 2 MLJ 334 (“Tung Kean Hin”)
- Judgment Length: 13 pages, 3,056 words
- Key Procedural Events: Judge Case Conference (JCC) on 18 November 2024; earlier JCCs on 7 May 2024 and 4 July 2024; Registrar’s Case Conferences on 16 August 2024, 20 September 2024 and 1 November 2024
Summary
In Banner (China) Investment Co Ltd v Ang Tjun Min Jimmy, the High Court addressed a narrow but practically significant civil procedure issue: how to obtain and select specimen signatures for submission to a common handwriting expert. The dispute arose because Mr Ang denied authorship of a signature on an audit confirmation relied upon by Banner to prove a large loan balance. After the court had appointed a common expert from the Health Sciences Authority (HSA), the parties became deadlocked on the process for obtaining signature samples, particularly whether Mr Ang could influence or choose which documents would be used as specimen signatures.
The court rejected Mr Ang’s position that he should be able to select the specimen signatures. While the court accepted the importance of integrity and authenticity in the handwriting comparison process, it held that this did not translate into a right for the disputed-signature party to choose the specimen documents. Instead, the court directed a structured process involving a corporate secretarial services company (Boardroom Corporate Services (Johor) Sdn Bhd, “BCS”) to generate a list of at least 15 documents that Mr Ang clearly would have signed, including documents whose signatures Mr Ang had not seen. Mr Ang would then be given an opportunity to respond and surface any specific concerns for the court’s consideration.
What Were the Facts of This Case?
Banner sued Mr Ang for repayment of a loan amounting to S$11,092,061.53. The claim was anchored on an audit confirmation dated 3 July 2020, which purportedly confirmed that Mr Ang owed Banner HK$65,955,196.76 as at 31 March 2018. Mr Ang’s defence was that the sum was advanced to him as a gift rather than a loan. More critically for present purposes, Mr Ang also challenged the authorship of the signature on the audit confirmation: he asserted that he did not sign the audit confirmation and that the signature was forged.
Because the authenticity of the signature was central to Banner’s case, Banner proposed that the parties appoint an expert from the Health Sciences Authority to conduct handwriting analysis of the signature on the audit confirmation. Mr Ang disagreed with the proposed expert source and instead suggested a forensic consultant from Malaysia. The dispute therefore initially concerned the appointment of the expert. At a Judge Case Conference on 7 May 2024, the parties were agreeable to appointing an HSA expert, and the court ordered that HSA be appointed as the common expert, with consequential directions on timelines for the expert’s report.
After the expert appointment, the parties encountered a second, more operational dispute: how to obtain signature specimens suitable for the HSA’s comparative analysis. The court had earlier directed that the parties identify signature specimens from documents filed in Singapore and Hong Kong court proceedings to determine whether those specimens would suffice for HSA’s requirements. If HSA required specimens from a different time period, the parties were to identify specimens from other sources where authorship was not disputed. The parties were also to confer on timelines and update the court.
Despite these directions, the parties struggled to obtain originals of documents signed by Mr Ang from the Hong Kong proceedings that would satisfy HSA’s requirements. Banner then proposed a joint request to BCS for originals of company documents in three Johor Bahru companies (“Three JB Companies”) in which Mr Ang was a director. Mr Ang disagreed. His solicitors emphasised that it was crucial that he chose the documents to be examined by HSA because his signature was in dispute. This disagreement brought the matter back before the court at the JCC on 18 November 2024, where the court had to decide the appropriate procedure for selecting specimen signatures.
What Were the Key Legal Issues?
The central legal issue was whether, in the context of handwriting comparison under the Evidence Act, Mr Ang had a right to select the specimen signatures that would be submitted to the common expert. Put differently, the court had to determine whether the need for authentic specimen signatures conferred procedural control on the party whose signature was disputed.
A related issue concerned the proper balance between (i) integrity of the specimen-signature selection process and (ii) fairness to the party disputing authorship. The court needed to ensure that the specimen signatures were genuinely attributable to Mr Ang (or at least “proved to the satisfaction of the court” to have been made by him), while also ensuring that the process did not become susceptible to manipulation by allowing the disputed-signature party to choose specimens that might undermine the expert’s comparative analysis.
Finally, the court had to consider how the Evidence Act provisions governing proof and comparison of signatures operate in practice. The judgment referenced ss 73 and 75 of the Evidence Act 1893 (2020 Rev Ed), which regulate the admissibility and use of signatures for comparison, including the requirement that comparison signatures must be admitted or proved to the court’s satisfaction to have been made by the relevant person.
How Did the Court Analyse the Issues?
The court began by situating the dispute within the broader procedural history. It noted that the court had already appointed HSA as the common expert and had issued earlier directions aimed at identifying suitable signature specimens. The later impasse was not about whether handwriting analysis was appropriate, but about the method for obtaining the specimen signatures that would form the basis of the expert’s comparative analysis.
In addressing Mr Ang’s asserted right to select specimen signatures, the court emphasised integrity in the process. It reasoned that allowing Mr Ang to be selective about which signature specimens were submitted to HSA would erode the integrity of the process. This was particularly important because the specimen signatures would be used to compare against the disputed signature on the audit confirmation. If the party disputing authorship could choose specimens, the process could be perceived as biased or potentially manipulated, undermining the evidential value of the expert analysis.
Second, the court stressed that the process must allow authentic signature specimens to be surfaced and identified. The court found that, on the facts, it was not disputed that Mr Ang was a director in the Three JB Companies identified by Banner, that he signed documents in that capacity, and that there would have been certain documents he must have signed as director. The court also noted that, under the directed process, Mr Ang would be allowed to provide his views on the list of documents identified by BCS. Any specific concerns could then be surfaced for the court’s consideration. This approach, the court held, preserved fairness without granting control over selection.
Third, the court considered Mr Ang’s reliance on a Malaysian decision, Tung Kean Hin. In Tung Kean Hin, the court had highlighted the pertinence of whether the plaintiff was the author of the specimen signatures provided for examination, because the authenticity of authorship is crucial to the comparative analysis. The High Court accepted the general proposition that authenticity of authorship matters. However, it held that the dicta in Tung Kean Hin did not support the proposition advanced by Mr Ang—that a party has a right to select specimen signatures for handwriting analysis. The court characterised Tung Kean Hin as underscoring the importance of ensuring authenticity, not conferring a procedural right to choose specimens.
Fourth, the court applied the Evidence Act framework. It reasoned that even if Mr Ang framed his position as merely wanting to verify authenticity rather than to select specimens, the practical import of his proposal was that he effectively selected the specimen signatures. The court then referred to s 75 of the Evidence Act, which makes clear that the disputed-signature party does not have a right to select the specimen signatures. Under s 75, a disputed signature can be compared to a signature that is “admitted or proved to the satisfaction of the court” to have been made by that person. The court’s point was that the selection and admissibility of comparison signatures must be controlled by the evidential rules and the court’s satisfaction, not by unilateral selection by the party whose signature is in issue.
Finally, the court articulated why a structured process was necessary in the circumstances. The parties had been at an impasse for a significant period. The court therefore needed a workable mechanism that would (i) generate specimen signatures with integrity, (ii) ensure that the specimens were authentic and attributable to Mr Ang, and (iii) provide a fair opportunity for Mr Ang to raise concerns about particular documents. The court concluded that these objectives could be achieved without permitting Mr Ang to choose the specimens outright.
What Was the Outcome?
The court issued directions requiring both parties to work with BCS to produce a list of at least 15 documents that the parties could agree Mr Ang would clearly have signed. The list had to include documents for which Mr Ang had not seen the signatures. The parties were to write to BCS within a week; BCS would respond within three weeks; and Mr Ang would provide his position on the list three weeks thereafter.
Practically, the effect of the outcome was to remove Mr Ang’s proposed control over which documents would be used as specimen signatures for HSA’s handwriting analysis. At the same time, the directions preserved procedural fairness by allowing Mr Ang to comment on the list and surface any specific concerns, which would then be considered by the court in the context of ensuring authenticity and integrity.
Why Does This Case Matter?
This decision matters because it clarifies how courts should manage specimen-signature selection in handwriting disputes. Handwriting analysis often turns on the quality and authenticity of the specimen signatures used for comparison. While parties may understandably want to protect themselves against unfair or unreliable specimen selection, the court drew a principled line: authenticity and integrity are essential, but they do not automatically translate into a right for the disputed-signature party to choose the specimens.
For practitioners, the case provides a useful procedural template. The court endorsed a structured, third-party-facilitated approach (through BCS) to generate a sufficiently large set of specimen documents, including documents the disputed party has not previously seen. This reduces the risk of selective or biased specimen selection and supports the evidential reliability of the expert’s comparative analysis. It also demonstrates that courts may rely on the Evidence Act’s comparison-signature framework to constrain procedural attempts to control specimen selection.
From a precedent perspective, the judgment reinforces that foreign dicta (such as from Tung Kean Hin) may be persuasive for general evidential principles, but will not be treated as authority for procedural rights not grounded in the local statutory scheme. The court’s reasoning is anchored in the Evidence Act provisions on comparison of signatures and the requirement that comparison signatures be admitted or proved to the satisfaction of the court. Accordingly, the case is likely to be cited in future disputes about specimen evidence, especially where one party seeks to influence the evidential basis of an expert report.
Legislation Referenced
- Evidence Act 1893 (2020 Rev Ed) — sections 73 and 75
Cases Cited
- Tung Kean Hin & Another (as executor for the estate of Tung Leong Geok, deceased) v Yuen Heng Phong (as administrator for the estate of See Ngan Sang @ Lee Ngan Sang) [2019] 2 MLJ 334
Source Documents
This article analyses [2025] SGHC 12 for legal research and educational purposes. It does not constitute legal advice. Readers should consult the full judgment for the Court's complete reasoning.